Molecular Partners AG annual ebitda margin
2019
2020
2021
2022
2023
2024
Molecular Partners AG's ebitda margin was −1,184.06% for fiscal 2024.
View full Molecular Partners AG company overview| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −1,184.06% | −350.19 pp |
| 2023 | 2023-12-31 | −833.87% | −896.64 pp |
| 2022 | 2022-12-31 | 62.76% | +686.64 pp |
| 2021 | 2021-12-31 | −623.88% | −30.57 pp |
| 2020 | 2020-12-31 | −593.31% | −425.57 pp |
| 2019 | 2019-12-31 | −167.74% | — |
Over the last five fiscal years, Molecular Partners AG's ebitda margin decreased from −167.74% to −1,184.06%, a change of −1016.32 percentage points.
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Molecular Partners AG source filings ↗